Business
Ventripoint Receives Medical Device License from Health Canada to Sell Next Generation, AI-powered, Heart-scanning Technology
(TheNewswire) Toronto, Ontario – TheNewswire - (August 21, 2024) - Ventr...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint Receives Medical Device License from Health Canada to Sell Next Generation, AI-powered, Heart-scanning Technology \n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Toronto, Ontario –\n \n\n TheNewswire -\n \n\n (August 21, 2024)\n \n\n -\nVentripoint Diagnostics Ltd.\n \n\n (\"\n \n\n Ventripoint\n \n\n \" or\nthe \"\n \n\n Company\n \n\n \"), (TSXV:VPT; OTC:VPTDF) a leader in whole heart\nanalysis, is pleased to announce that it\n \n\n has\nreceived a Medical Device License from Health Canada for its latest\nproduct offering, VMS+4.0. This is a major milestone for Ventripoint\nas it continues to innovate and provide cutting-edge solutions to\ncardiac clinicians worldwide.\n \n\n\n\n VMS+4.0 offers a significant improvement in user\nexperience through the automation of the image processing steps. This\nstreamlined workflow leads to a significant reduction in operator time\nwithout compromising the accuracy of the measurements. Additionally,\nthis release is optimized to work seamlessly with Ventripoint’s\nrecently announced magnet-free sensors, further enhancing efficiency,\nease of use and applicability.\n \n\n\n\n “We are delighted to receive the license and will\nimmediately introduce the enhanced capabilities of the new version to\nCanadian cardiologists and healthcare providers,” said Ventripoint\nPresident and CEO, Hugh MacNaught. “The advances introduced in\nVMS+4.0 enable its use for patients with intracardiac devices such as\npacemakers and defibrillators, who cannot go into an MRI. This\nengineering breakthrough enlarges our market opportunity as it now\nempowers healthcare providers with a powerful tool that delivers\naccurate and reliable cardiac measurements in a more efficient manner\nand without the restrictions associated with MRI.”\n \n\n\n\n VMS+4.0 will be marketed as a premium product in Canada\nto complement our base product VMS+3.0, which has already received\nregulatory clearances from US-FDA, Health Canada, the United Kingdom\n(U.K.) and the European Union (E.U.) and is being used by leading\nhospitals in the U.S., E.U., U.K. and Canada.\n \n\n\n\n About Ventripoint Diagnostics\nLtd.\n \n\n\n\n Ventripoint\n \n\n is an industry leader\nin the application of AI (Artificial Intelligence) to\nechocar...